We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Hits Snooze Button on Neurocrine's Sleep Drug

Law360 (September 5, 2006, 12:00 AM EDT) -- Further clouding the future of insomnia drug Indiplon, Neurocrine Biosciences Inc. said on Tuesday that the FDA has asked it to reanalyze safety and efficacy data because of issues raised in an initial review.

The FDA initially approved two low-dose versions of Indiplon, but issued a non-approval letter for the higher and longer lasting 15-mg dose.

Indiplon is a drug that acts on a specific site of the GABA-A receptor in the brain believed to be responsible for promoting sleep.

The original application for Indiplon was...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.